Dr. Sayed is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
101 Manning Dr
Department of Internal Medicine
Chapel Hill, NC 27514Phone+1 919-966-1072Fax+1 919-843-2356
Education & Training
- University of North Carolina HospitalsResidency, Dermatology, 2010 - 2013
- University of North Carolina HospitalsInternship, Internal Medicine, 2009 - 2010
- University of North Carolina at Chapel Hill School of MedicineClass of 2009
Certifications & Licensure
- NC State Medical License 2009 - 2025
- American Board of Dermatology Dermatology
Clinical Trials
- A Randomized Controlled Trial Evaluating the Efficacy of Intralesional Triamcinolone in Hidradenitis Suppurativa. Start of enrollment: 2016 Jun 01
Publications & Presentations
PubMed
- 193 citationsNorth American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Par...Ali Alikhan, Christopher Sayed, Afsaneh Alavi, Raed Alhusayen, Alain Brassard
Journal of the American Academy of Dermatology. 2019-07-01 - 20 citationsDevelopment and validation of IHS4-55, an IHS4 dichotomous outcome to assess treatment effect for hidradenitis suppurativa.Thrasivoulos Tzellos, Kelsey R van Straalen, Athanassios Kyrgidis, Afsaneh Alavi, Noah Goldfarb
Journal of the European Academy of Dermatology and Venereology. 2023-02-01 - 67 citationsEfficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa: A Phase 2, Double-blind, Placebo-Controlled Randomized Clinical Trial.Sophie Glatt, Gregor B.E. Jemec, Seth B Forman, Christopher Sayed, George Schmieder
JAMA Dermatology. 2021-11-01
Books/Book Chapters
Lectures
- Advanced Management Strategies for Hidradenitis SuppurativaAmerican Academy of Dermatology - Annual Meeting 2019 - Washington, D.C. - 3/2/2019
- Development of the North American Clinical Guidelines for Hidradenitis SuppurativaAmerican Academy of Dermatology Annual Meeting, Orlando, FL. - 2/2018
- Office-Based Procedures for Hidradenitis SuppurativaAmerican Academy of Dermatology Annual Meeting, Orlando, FL - 2/2018
Press Mentions
- Diagnosing Mild Hidradenitis Suppurativa: Early Stage Can Mimic Other DiseasesMay 21st, 2024
Research History
- Co-investigatorA Phase 4, Double-Blind, Randomised,Placebo-Controlled Multicenter Study to Assess the Safety and Efficacy of Adalimumab Used in Conjunction with Surgery in Subjects with Moderate to Severe Hidradenitis Suppurativa.2018 - Present
- Principal InvestigatorGenome-wide association study of patients with hidradenitis suppurativa.2018 - Present
- Principal Investigator• UCB Biopharma SPRL, HS0001, A Phase 2 Multicenter, Investigator-Blind, Subject-Blind, Placebo-Controlled Study Of The Efficacy, Safety, And Pharmacokinetics Of Bimekizumab In Subjects With Moderate To Severe Hidradenitis Suppurativa (HS).2018 - Present
- Principal InvestigatorA randomized, double-blind, placebo-controlled, multicenter Phase II study to determine efficacy and safety of IFX-1 in subjects with moderate to severe hidradenitis suppurativa (SHINE). 2018.2018 - Present
- Co-investigatorA Phase 2, Multi-Center, Evaluator-Blind, Randomized, Vehicle-Controlled Study to Compare the Safety and Efficacy of IDP-118 Lotion to Ultravate® (halobetasol propionate) Cream, 0.05% in the Treatment of Plaque Psoriasis.2017 - Present
- Co-investigatorAn Observational, Multicenter Disease Registry to Evaluate Clinical Practice Trends and Outcomes in Adult Patients with Hidradenitis Suppurativa.2014 - Present
- Co-investigatorA 52-week, multicenter, randomized, double-blind study of secukinumab (300 mg) to demonstrate efficacy as assessed by Psoriasis Area and Severity Index and Investigator's Global Assessment after 12 weeks of treatment, compared to ustekinumab, and to assess long term safety, tolerability, and efficac2016 - 2018
- Principal InvestigatorFull transcriptome analysis in lesional and non-lesional skin of hidradenitis suppurativa with intention to identify disease signatures and understand molecular mechanism of disease.2016 - 2018
- Co-investigatorSafety, Pharmacokinetics and Preliminary Efficacy of Asimadoline in Pruritus Associated With Atopic Dermatitis2017 - 2017
- Principal InvestigatorA randomized, controlled, double blind study to evaluate the efficacy of intralesional triamcinolone in the treatment of hidradenitis suppurativa.2016 - 2017
- Co-investigatorA Phase IIa, Randomized, double-blind, placebo-controlled, multicenter study to assess the safety, tolerability and preliminary efficacy of MEDI8968 in Subjects with Moderate to Severe Hidradenitis Suppurativa (HS).2014 - 2015
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: